medigraphic.com
Instituto Nacional de Salud Pública

2018, Number 2

<< Back Next >>

salud publica mex 2018; 60 (2)

Prognostic factors in patients with breast cancer and brain metastasis as the first site of recurrence

Mohar-Betancourt A, Alvarado-Miranda A, Torres-Domínguez JA, Cabrera P, Lara-Medina F, Villarreal-Gómez YS, Reynoso-Noverón N

Language: Spanish
References: 34
Page: 141-150
PDF size: 479.52 Kb.


ABSTRACT

Objective. To evaluate the prognostic factors (clinicalpathological characteristics and treatments) in patients with breast cancer and metastasis to central nervous system (CNS) as the first site of the disease. Materials and methods. Kaplan-Meier method and life tables were used to estimate overall survival time over a retrospective cohort of 125 breast cancer patients treated at the Instituto Nacional de Cancerología (INCan) during 2007-2015, who presented metastasis to the CNS as the first site of extension of the disease. The cox proportional hazards model was used to determine the prognosis factors. Result. The median overall survival time was 14.2 months (IC95%: 11.83-26.93). Patients with triple negative (TN), according to inmunohistochemistry analysis classification, had lower survival times (p=0.0004) and had a risk of dying two times (p=0.037) higher than patients with a different immunophenotype (HR: 2.77. 95%CI: 1.10-6.99). The degree of intermediate SBR increases the risk of dying in patients with metastasis (HR 2.76, 95% CI: 1.17-6.51). Conclusion. CNS metastasis continues to be a poor prognostic factor that reduces survival and affects quality of life. It is recommended to monitor the early pres ence of clinical neurological manifestations during follow-up for prompt treatment. TN patients have worse prognosis and HER2+ a better control.


REFERENCES

  1. Wiltzel I, Olivera-Ferrer L, Pantel K, Müller V, Wikman H. Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res. 2016;18(1):8. https://doi.org/10.1186/s13058-015-0665-1

  2. Nayak L, Lee E, Wen P. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48-54. https://doi.org/10.1007/s11912-011-0203-y

  3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0. Cancer incidence and mortality worldwide [documento en internet]. Lyon: International Agency for Research on Cancer (IARC Cancer Base, núm. 11), 2013 [citado jun 12, 2017]. Disponible en: http://globocan.iarc.fr

  4. Organización Mundial de la Salud [página de internet]. Cáncer de mama: prevención y control; [aprox. 5 pantallas] [citado mayo 17, 2017]. Ginebra: OMS, 2017. Disponible en: http://www.who.int/topics/cancer/breastcancer/ es/index1.html

  5. Instituto Nacional de Estadística y Geografía. Estadísticas a propósito del día mundial de la lucha contra el cáncer de mama. Estadístico. Aguascalientes: INEGI, 2016.

  6. Sierra MS, Soerjomataram I, Antoni S, Laversanne M, Piñeros M, De Vries E, et al. Cancer patterns and trends in Central and South America. Cancer Epidemiol. 2016;44(suppl 1):S23-S42. https://doi.org/10.1016/j. canep.2016.07.013

  7. Soto-Perez-de-Celis E, Chavarri-Guerra Y. National and regional breast cancer incidence and mortality in Mexico 2001-2011: analysis of a population-based database. Cancer Epidemiol. 2016;41:24-33. https://doi. org/10.1016/j.canep.2016.01.007

  8. Leone J, Leone B. Breast cancer brain metastases: the last frontier. Exp Hematol Oncol. 2015;4:33. https://doi.org/10.1186/s40164-015-0028-8

  9. Yan M, Lü H, Liu Z, Liu H, Zhang M, Sun X, et al. High risk factors of brain metastases in 295 patients with advanced breast cancer. Chin Med J (Engl). 2013;126(7):1269-1275.

  10. Matus-Santos J, Motola-Kuba D. Importancia de la detección de metástasis cerebrales en pacientes con carcinomas en estadios avanzados. Rev Invest Med Sur Mex. 2012;19(4):222-7.

  11. Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Goncalves A. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012;32(11):4655-62.

  12. Altundag K, Bondy ML, Mirza NQ, Kau SW, Broglo K, Hortobagyi GN et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patient with central nervous system metastasis. Cancer. 2007;110(12):2640-47. https://doi.org/10.1002/cncr.23088

  13. Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Zacharenia S, Kazakou I, et al. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Breast Cancer Res. 2006;8(4):R36. https://doi.org/10.1186/bcr1516

  14. Ishihara M, Mukai H, Nagai S, Onozawa M, Nihei K, Shimada T, et al. Retrospective anlysis of risk factors for central nervous system metastases in operable breast cancer. Oncology. 2013; 84:135-40. https://doi. org/10.1159/000345321

  15. Seperduto P, Kased N, Roberge D, Xu Z, Shanley R, Lou X et al. The effect of tumor subtype on survaival and the graded prognostic assessment (GPA) for patients with breat cancer and brain metastases. Int J Radiat Oncol Biol Phys. 2011;82(5):2111-17. https://doi.org/10.1016/j. ijrobp.2011.02.027

  16. Harvey J, Clark G, Osborne C, Allred D. Estrogen receptor status by inmunohistochemeistry is superior to the ligand-blinding assay for predicting response to adyuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474-81. https://doi.org/10.1200/JCO.1999.17.5.1474

  17. Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/college of American Pathologist clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241-56. https://doi.org/10.5858/arpa.2013-0953-SA

  18. American Joint Committee on Cancer [página de internet]. Chicago: AJCC, 2017. Cancer Stging System; [aprox. 4 pantallas] [citado dic 8, 2017]. Disponible en: https://cancerstaging.org/references-tools/Pages/What-is-Cancer-Staging.aspx

  19. Meyer JS, Alvarez C, Milikowsi C, Olson N, Russo I, Russo J et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathology. 2005;18:1067-78. https://doi.org/10.1038/ modpathol.3800388

  20. Dowsett M, Nielsen TO, A´Hern R, Barlett J, Coombes RC, Cuzick J et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103(22):1656-64. https://doi.org/10.1093/jnci/djr393

  21. Harrell FJ, Lee K, Mark D. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-87. https://doi.org/10.1002/ (SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4

  22. Holleczek B, Brenner H. Trends of population-based breast cancer survival in Germany and the US. BMC Cancer. 2012;12:317. https://doi.org/10.1186/1471-2407-12-317

  23. Rock C, Demark-Wahnefried W. Can lifestyle modification increase survival in women diagnosed with breast cancer. J Nutr. 2002;132 (suppl 11):3504S-3507S. https://doi.org/10.1093/jn/132.11.3504S

  24. Ogawa K, Yoshii Y, Nishimaki T, Tamaki N, Miyaguni T, Tsuchida Y, et al. Treatment and prognosis of brain metastases from breast cancer. J Neurooncol. 2008;86(2):231-8. https://doi.org/10.1007/s11060-007-9469-1

  25. Anders C, Deal A, Miller C, Khorram C, Meng H, Burrows E et al. The prognostic contribution of clinical breast cancer subtype, age and race among patients with breast cancer brain metastases. Cancer. 2010;117(8):1602-11. https://doi.org/10.1002/cncr.25746

  26. Eichler A, Kuter I, Ryan P, Schapira L, Younger J, Henson J. Survival in patientes with brain metastases from breast cancer. Cancer. 2008;112(11):2359-2367. https://doi.org/10.1002/cncr.23468

  27. Rostami R, Mittal S, Rostami P, Tavassoli F, Jabbari B. Brain metastasis in breast cancer: a cmprehensive literature review. J Neurooncol. 2016;127(3):407-14. https://doi.org/10.1007/s11060-016-2075-3

  28. Reyes ME, Takeo F, Branstetter D, Krishnamurthy S, Masuda H, Wang X, et al. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat. 2017;164(1):57-67. https://doi.org/10.1007/s10549-017-4233-5

  29. Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticochea A, et al. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumporigenesis and metastasis. Cancer Res. 2012;72(11):2879-88. https://doi. org/10.1158/0008-5472.CAN-12-0044

  30. Man-Hsin H, Chun-Yu L, Cheng-Ying S, Chin-Yi H, Yi-Fang T, Yu-Ling W, et al. Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patientes. Plos One. 2014;9(2): e89389. https:// doi.org/10.1371/journal.pone.0089389

  31. Harputluoglu H, Dizdar O, Askoy S, Kilickap S, Dede DS, Ozisik Y, et al. Characteristics of breast cancer patients with central nervous system metastases: a single-center experience. J Natl Med Assoc. 2008;100(5):521-33. https://doi.org/10.1016/S0027-9684(15)31298-0

  32. Ospino R, Cendales R, Triana J. Supervivencia en pacientes con metástasis cerebrales tratados con radioterapia holoencefálica en el Instituto Nacional de Cancerología. Rev Colom Cancerol. 2009;14(1):29-36.

  33. Kühnöl J, Kühnöl C, Vordermark D. Radiotherapy of brain metastases from breast cancer. Oncol Lett. 2016;11(5):3223-27. https://doi. org/10.3892/ol.2016.4349

  34. Fenner M, Possinger K. Chemotherapy for breast cancer brain metastases. Oncol Res. 2002;25(5):474-9. https://doi.org/10.1159/000067443




2020     |     www.medigraphic.com